文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

移植后环磷酰胺时代造血细胞移植结局:全面供者分析

Hematopoietic Cell Transplantation Outcomes in the Era of Post-Transplant Cyclophosphamide: Comprehensive Donor Analysis.
PubMed 文献 · Blood Adv · 2026-10-21

该多中心回顾性队列研究基于CIBMTR数据,纳入2017-2023年首次接受PTCy预防GVHD的12,617例急性白血病或MDS成人患者。调整供者年龄后,MUD、MMUD和单倍体供者的OS均低于MSD,但排除供者年龄调整后MUD与MSD的OS相似,提示PTCy缩小了供者类型间的结局差异。

要点

  • PTCy时代MSD仍与最佳OS相关,但MUD与MSD的GRFS相似。
  • MMUD和单倍体供者OS较低,但复发风险均低于MSD。
  • 供者选择不应固守等级,应使用可及的最佳供者及时移植。

核心结论

  • PTCy缩小了不同供者类型间的结局差异,支持从 rigid 供者等级转向及时使用最佳可及供者进行HCT。

研究设计与样本

  • 多中心回顾性队列研究,使用CIBMTR数据,纳入2017-2023年首次HCT的急性白血病或MDS成人,均接受PTCy为基础的GVHD预防。
  • 主要队列12,617例:MSD 1,263例,MUD 4,117例,MMUD 1,426例,单倍体供者5,811例。

主要发现

  • 与MSD相比,MUD的OS较低(HR 1.16,95%CI 1.00-1.34,p=0.004),MMUD的OS较低(HR 1.32,95%CI 1.12-1.55,p<0.001),单倍体供者的OS较低(HR 1.43,95%CI 1.24-1.64,p<0.001)。
  • MUD与MSD的GRFS相似,MMUD和单倍体供者的GRFS较低。
  • 与MSD相比,其他供者组复发风险较低,但非复发死亡率和急性GVHD较高,慢性GVHD相似。
  • 敏感性分析排除供者年龄调整后,MUD和MMUD的OS与MSD相似,MUD的GRFS改善,MMUD和单倍体供者的GRFS与MSD相似。

临床怎么用

  • 在PTCy时代,供者选择可减少对传统供者等级的依赖,优先及时使用最佳可及供者进行HCT。

局限性

  • 回顾性队列研究设计。
  • 主要分析调整了供者年龄,敏感性分析排除供者年龄调整后结果有所变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Donor types influence outcomes after allogeneic hematopoietic cell transplantation (HCT), but their relative impact in the post-transplant cyclophosphamide (PTCy) era is uncertain. We performed a multicenter retrospective cohort study using Center for International Blood and Marrow Transplant Research data for adults with acute leukemia or myelodysplastic syndromes undergoing first HCT from matched sibling donors (MSD), 8/8 matched unrelated donors (MUD), 7/8 mismatched unrelated donors (MMUD), or haploidentical donors between 2017 and 2023 with PTCy-based graft-versus-host disease (GVHD) prophylaxis. The primary cohort included 12,617 patients: 1,263 MSD, 4,117 MUD, 1,426 MMUD, and 5,811 haploidentical recipients. In multivariable models adjusted for donor age and clinical covariates, overall survival (OS) was lower with MUD (hazard ratio [HR], 1.16; 95% CI, 1.00-1.34, p=0.004), MMUD (HR, 1.32; 95% CI, 1.12-1.55, p<0.001), and haploidentical donors (HR, 1.43; 95% CI, 1.24-1.64, p<0.001) compared with MSD. GVHD-free, relapse-free survival (GRFS) was similar for MUD and MSD (reference) but lower with MMUD and haploidentical donors. Compared to MSD, all other donor groups had lower relapse risk but higher non-relapse mortality and acute GVHD, with similar chronic GVHD. In sensitivity analyses excluding donor-age adjustment, compared to MSD, OS was similar for MUD and MMUD, and GRFS was improved with MUD and similar for MMUD and haploidentical donors. These findings suggest that PTCy narrows outcome differences across donor types, shifting donor selection from rigid hierarchies and supporting timely HCT using the best available donor.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Aljawai YM, Ueda Oshima M, Astha V, et al. Hematopoietic Cell Transplantation Outcomes in the Era of Post-Transplant Cyclophosphamide: Comprehensive Donor Analysis. Blood Adv. 2026. PMID: 42907170. doi:10.1182/bloodadvances.2026021883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。